Sagimet Biosciences (SGMT) Current Assets (2022 - 2026)

Sagimet Biosciences' Current Assets history runs 5 years deep, the most recent figure standing at $107.7 million for Q1 2026.

• On a quarterly basis, Current Assets fell 26.26% year-over-year to $107.7 million in Q1 2026; TTM through Mar 2026 was $107.7 million, a 26.26% decrease from a year earlier, with the FY2025 full-year figure at $116.4 million, down 23.81% from the prior year.
• Current Assets fell to $107.7 million in Q1 2026 per SGMT's latest filing, from $116.4 million in the prior quarter.
• Across five years, Current Assets topped out at $194.5 million in Q1 2024 and bottomed at $21.4 million in Q2 2023.
• The 5-year median for Current Assets is $119.5 million (2025), against an average of $118.6 million.
• Across the five-year window, Current Assets soared 680.89% in 2024 and slipped 26.26% in 2026, its largest moves.
• Year by year, Current Assets stood at $32.8 million in 2022, then soared by 194.72% to $96.6 million in 2023, then surged by 58.08% to $152.8 million in 2024, then fell by 23.81% to $116.4 million in 2025, then declined by 7.46% to $107.7 million in 2026.
• Per Business Quant, the three latest SGMT Current Assets figures stand at $107.7 million (Q1 2026), $116.4 million (Q4 2025), and $119.5 million (Q3 2025).